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PCR technique was used as an alternative method to detect evidence of rinderpest virus for diagnosis 
and in epidemiological surveys. Viral RNA was purified in 20 to 30 min using a commercial kit (RNaid 
(BIO 101). Primers used mapped in the nucleocapsid protein gene of rinderpest virus and gave specific 
and sensitive amplification from pathological samples. The size of the amplified fragment was 297 bp 
and the result was confirmed using internal non-radioactive probe SB1. The specificity of the PCR 
products was also confirmed by cleavage using restriction enzyme RsaI to give a major band of 200 bp. 
 





Rinderpest (RP) is a highly contagious disease of cattle, 
buffaloes and some wild animals, and is caused by the 
rinderpest virus (RPV). The disease has a very high 
mortality (Scott, 1964; Plowright, 1968) and was one of 
the most economically important animal diseases in 
Africa, the Middle-East and Asia. Eradication campaigns 
have now almost completely eliminated the virus and 
rapid diagnosis and surveillance are keys to monitoring 
any possible foci and possible spread. Small ruminants 
can also be infected with RPV causing an acute disease 
(Shaila et al., 1989; Anderson et al., 1990), however 
some asymptomatic infections can occur (Couacy-
Hymann et al., 1995). In the same geographical areas 
small ruminants can suffer from peste-des–petits-
ruminants (PPR) which is caused by PPR virus (PPRV). 
There is a close relationship between the two viruses and 
they belong to the Morbillivirus genus of the 
paramyxoviridae family (Gibbs et al., 1979). In small 
ruminants, both diseases are clinically very similar, 
making it impossible to differentiate them in the field.  
The rinderpest eradication programme has been very 
successful. In Africa, the Western and Central regions 
have  ceased  vaccination in all species and the countries  
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are cerified free from rinderpest disease with the OIE. In 
May 2005, Benin, Eritrea, Senegal and Togo were 
declared free from rinderpest infection by the OIE. 
Epidemiological surveillance was launched in 2000 
through the Pan African Control for Epizootic diseases 
programme (PACE) with the aim of proving the absence 
of rinderpest infection in the animal population. Detection 
of specific antigens and antibodies was needed to 
provide methods to clearly differentiate both RPV and 
PPRV during this phase. 
Classical techniques for diagnosis and survey of 
rinderpest, such as virus isolation and agar gel immuno-
diffusion, viral neutralisation test, are time consuming and 
not sensitive enough particularly for the complications 
inherent where mild strains of RPV are presented. Such 
strains produce minor or no clinical signs and only low 
levels of viral antigen from ocular secretions in infected 
animals (Wamwayi et al., 1995). The detection and 
elimination of such mild strains requires a new generation 
of diagnostic tests (Taylor, 1986). On the other hand, it is 
essential to differentiate clearly RPV from PPRV in small 
ruminants. Thus specific and sensitive techniques are 
needed to confirm any cases of rinderpest. 
Molecular techniques have been developed to 
differentiate PPRV and RPV: Diallo et al., (1989) deve-
loped radioactive probes with the nucleoprotein (Np) 
genes of RPV and PPRV but these are applicable only in 
a well equipped laboratory; Pandey et al. (1992) develop- 




Table 1. Sequence and position of primers set and oligonucleotide probe. 
 
Primer Gene (Position) Sequences 
B12 RP-N (1322>1344) 5’ CAA GGG AGT GAG GCC CAG CAC AG 
B2 RP-N (1594<1618) 5’ TAG GAA CAG CAA CAT ACG AGA GTC 
Probea 




ed non-radioactive probes and Libeau et al. (1994) 
differentiated RPV from PPRV by an immunocapture 
ELISA also based on the Np genes. However their 
sensitivity is lower than the radioactive ones. In such 
case, a specific and sensitive test to detect the virus in 
clinical samples is needed. This paper describes the 
investigation of a reverse-transcription – PCR (RT-PCR) 
technique for the specific diagnosis of RPV. The study 
uses the Np gene of RPV to distinguish all RPV strains 
from those of PPRV and also report on the use of the 
technique in epidemiological surveys for RP. 
 
 
MATERIALS AND METHODS 
 
Cells and viruses 
 
Vero cells were grown in Eagle’s MEM supplemented with 10% 
foetal calf serum and 1%   antibiotic solution (GIFCO). Each 25 cm2 
flack received 10 ml of approximately 25,000 cells/ml and 200 µl of 
each of a specific RPV strain, and then incubated at 37°C (5% of 
CO2 atmosphere). When confluent monolayer cells were 
established, the foetal calf serum was reduced to 1%. This medium 
was replaced every two days.  The infected cells and supernatant 
were taken when the cytopathic effect (cpe) reached 50% 




Origin of the RPV strains  
 
Thirteen strains from CIRAD/EMVT (Montpellier, France) were used 
and RNA of each strain was extracted. These were RBOK 
(attenuated vaccine strain), RPVL (Japan, lapinized RPV strain), 
Buffalo Nigeria (Nigeria), Egypt, RGK (Kenya), RBT/1 (Tanzania), 
Sokoto (Nigeria), Iraq, Lebanon, Pakistan, Pendik (Turkey), Saudi 
(Saudi Arabia), Yemen. 
The RNA from twelve PPRV strains was obtained under the 
same conditions, to check the specificity of primers. These were 
PPRV 75/1 (vaccine strain), PPRV 75/1 (wild strain), Burkina-Faso, 
Côte-d’Ivoire, Central African Republique, Egypt, Mieliq, Senegal, 
Sudan-Sennar, Dorcas, Ibri, Israel.  
 
 
Extraction of RNA  
 
RNA was extracted as described by Yamada et al. (1990) modified 
by Couacy-Hymann et al. (2002).  Briefly, 10 µl of RNaid (BIO 101) 
were added to a mixture containing 100 µl of 6M-guanidine 
isothiocyanate (lysis solution), in a 0.5 ml tube. After mixing, this 
was stirred slowly at room temperature for 5 min and centrigfuged 
at 2000 rpm for 2 min in a microfuge. The supernatant was 
discarded and the pellet washed three times with 400 µl of ethanol 
solution (EtOH 50%, Tris-HCl 10 mM pH 7.4-7.6, EDTA 1mM, NaCl 
50 mM). The pellet was vacuum dried and RNA bound to the matrix 
Rnaid was eluted by 30-75 µl of DEPC-treated water for 5 min at 
55°C, followed by centrifugation at 15000 rpm for 5 min. The 
supernatant contained the total RNA and 1 µl of RNA inhibitor (10 
U/µl) (Amersham-Pharmacia-Biotech) was added to RNA solution 
which was then kept at –70°C until the RT–PCR procedure. This 
method was used to extract RNA from experimentally infected 
animals and field samples such as lymph nodes, nasal discharges, 
lungs, mouth swabs. 
 
 
RPV primers and probes 
 
One set of specific primers was selected in the 3’-terminal region of 
the NRPV gene after alignment of both Np genes of RPV (Kamata 
et al., 1991) and PPRV (Diallo et al., 1994) to allow the 
amplification of a sequence of 297 bp of any RPV strains.  
A specific probe was chosen in the fragment amplified by the set 
of primers B12/B2 and labelled with digoxigenin-dUTP using the 
non-radioactive DNA labelling kit (Boehringer) following the 
manufacturers’ instructions. The name sequence and location of 
the primers and probe are summarized in Table 1. The 




Single-strand cDNA synthesis 
 
Extracted RNA (1 µl) of each RPV strain was each mixed with 7 µl 
of DEPC-treated water and 1 µl of each primer (30 pmol/µl) in a 0.5 
ml tube. The mixture was briefly stirred, centrifuged at 2000 rpm for 
a few seconds then incubated at 65°C for 10 min. The tube was 
chilled on ice and centrifuged briefly as before. Then 1 µl of RNase 
(10 U/µl) (RNaguard, Amersham-Pharmacia Biotech) and 5 µl of 
cDNA synthesis mix (first strand cDNA kit, Amersham-Pharmacia 
Biotech) was added, followed by a short centrifugation at 2000 rpm 





The PCR reaction was made on the contents of the reaction in the 
tubes above, which received the following reagents: 10 µl of Taq 
polymerase buffer 10X, 0.8 µl of dNTPs (25 mM), 1 µl of each 
primers (30 pmol/µl), 71.2 µl of distilled water. The tube was stirred, 
centrifuged briefly, denatured at 95°C for 10 min; chilled on ice; 
centrifuged briefly at 2000 rpm and then promptly, 1 µl of Taq 
polymerase (2.5 U/µl) was added. The amplification reaction was 
made in a PHC3 thermal cycler (Techne). Temperature cycling was  
60°C for 1 min, for annealing; 72°C for 30 s for extension; 94°C for 
30 s for denaturation; repeated for 5 cycles followed by 30 cycles 
where temperature of annealing was reduced to 55°C. All samples 
were for 36 cycles including the final extension at 72°C for 10 min. 
To avoid  false  positive  results, the good practices as described by  






Figure 1.  Specific PCR amplicafication of the NP gene fragment of different RPV isolates with primers B12/B2. 
The amplified products analysed by electrophoresis on 2% agarose gel stained with ethidium bromide are as 
follow: M (Marker, Boerhinger, Marker VI); (1) RBOK; (2) RPVL; (3) Buffalo Nigeria; (4) Egypt; (5) RGK; (6) RBT/1; 
(7) Sokoto; (8) Irak; (9) Lebanon; (10) Pakistan; (11) Pendik; (12) Saudi; (13) Yemen; (14) Negative control 





Figure 2. Attempt of specific PCR amplicafication of the NP gene fragment of different PPRV isolates with primers 
B12/B2. The amplified products analysed by electrophoresis on 2% agarose gel stained with ethidium bromide are 
indicated as follow: M (Marker, Boerhinger, Marker VI); (1) Positive control (RBOK, RPV vaccine strain); (2) PPRV 
75/1 (Vaccine strain); (3) PPRV 75/1 (wild strain); (4) Burkina-Faso; (5) Côte-d’Ivoire; (6) Central African 




Kwok and Higuchi (1989) were followed. Negative and positive 
controls were included in all experiments 
 
 
Direct analysis of PCR-amplified products 
 
Each amplified sample (10 µl) was electrophoresed on a composite 
1% NuSieve and 1% Seakem agarose gel (FMC) in Tris-borate 
EDTA buffer 1X (0.089 M Tris base, 0.089 M boric acid and 0.02 M 
EDTA, pH 8) either directly or after digestion by restriction enzyme 
RsaI (Boerhinger). The size of the fragments was examined under 
UV illumination. The gel was transferred onto nylon filter positive 
(Boehringer) charged by capillary action overnight using 0.4 N 
NaOH as medium. Restriction enzyme digestion of PCR-products 




Southern-blot hybridisation  
 
A nylon filter containing immobilised DNA was pre-hybridized in 5 
ml of hybridisation buffer composed of SSC 5X, 2% blocking 
reagent (Boerhinger), 0.1 % sarcosine, 0.02% SDS, for 30 min and 
incubated at 68°C in an hybaid-hybridisation-oven. This was 
followed by a hybridisation buffer step with 2.5 ml of a new 
hybridisation buffer, 12.5 µl (about 10 pmol/ml) of the corresponding 
internal SB1digoxigenin–dUTP probe and incubated for 30 min at 
50°C in the hybridisation oven. After hybridisation, the probe was 
recovered and frozen at –20°C for future use. The filter was washed 
with the washing buffer. Firstly, at room temperature with 10 ml of 
the washing buffer: SSC 2X, 0.1% SDS for 5 min (twice) and 
secondly, at 50°C with 10 ml of the washing buffer containing SSC 
0.1% and 0.1% SDS for 10 min (twice). The presence of 
digoxigenin was revealed by immunological detection with 





The extraction method using the RNaid system gave 
RNA of good quality and yield in 30 min from diverse 
samples (infected cell culture, experimentally infected 
animals and field samples (data not shown). The primers 
B12/B2 were used successfully to specifically amplify the 
Np gene of RPV after extracting the RNA. An ethidium 
stained gel of Np RPV PCR-products from these isolates 
is shown in Figure 1. The size of amplified products is 
297 bp as expected. Both negative controls (distilled 
water and uninfected Vero cells replacing RNA) remained 
negative as shown in lanes 14 and 15, respectively. After 
southern-blot transfer of all the PCR-products onto the 
membrane, the internal and non-radioactive probe SB1 
served for the hybridisation. It detected the transferred 
cDNA products confirming that the correct fragment was 
obtained (data not shown).  
The primers B12/B2 were unable to amplify RNA of 
PPRV obtained from infected cells (Figure 2). After diges- 






Figure 3. Specific PCR amplification of the NP gene of RPV 
isolates with primers B12/B2. The amplified products were then 
restricted with Rsa1 at 37°C for 1 h. There were 5 restricted RPV-
amplified-products with a major band at 200 pb (R); Positive and 




tion by RsaI, a major band of 200 bp was obtained. The 
expected fragments of 47 bp and 50 bp cannot be seen 
with this agarose gel (Figure 3). This study was also 
performed with the PCR-products of PPRV strains with 
primers P1/P2 and showed that RsaI was unable to 
cleave these amplified fragments (Couacy-Hymann, 
1994). 
RNA was extracted from lungs, nymph nodes,  nasal 
discharges, mouth swabs, collected from experimental 
infected cattle and from controls were subjected to RT-
PCR. The expected fragment of 297 bp appeared in each 
infected sample whereas the control ones remained 
negative (data not shown).  Field samples since 1995 
were all negative. This set of primers failed to amplify 
measles virus from samples collected from sick children 






The extraction of RNA for RT-PCR remains a critical 
factor in diagnostic sensitivity (DSn) and diagnostic 
specificity (DSp) of testing. This step requires an efficient 
method to obtain a good quality material. The rapid 
procedure for RNA extraction described previously was 
very successful (Couacy-Hymann, 1994; Couacy-
Hymann et al., 2002) and was simpler and easier for use 
in routine diagnosis than previous phenol-chloroform 
based extraction methods (Chomczynsky and Sacchi, 
1987; Ausubel et al., 1993). The use of commercial kits 
for RNA purification and reverse transcriptase reaction 
avoids manipulation steps. The incorporation of guani-
dine isothiocyanate in the lysis solution efficiently 
inactives RNase to prevent RNA degradation. Samples in 
this solution do not require any cold chain which is very 
important in the field in Africa conditions.The specificity of 
the set of primers B12/B2 was confirmed as they did not 





Additional confirmation came from the restriction enzyme 
data where RsaI cleaved the amplified fragments of RPV 
but not the Np of PPRV. The DSn of the RT-PCR applied 
to RPV diagnosis is equivalent to the PPRV tests for 
PPRV diagnosis where it was shown that RT-PCR was 
1000 fold more sensitive than the classical titration test 
(Couacy-Hymann et al., 2002). This sensitivity could be 
increased with the non-radioactive probe SB1. 
The RT-PCR technique followed by a hybridisation with 
a specific non-radioactive probe SB1 or by a cleavage by 
a specific restriction enzyme, RsaI, is a powerful tool for 
RPV diagnosis and differential diagnosis of RPV in the 
Morbillivirus genus, in particular between  RPV and 
PPRV. Techniques involving RT-PCR for the diagnosis of 
RPV were first developed in 1992 and validated with 
reference to experimentally infected animals and on field 
samples. Using the fusion protein (Fp) gene of RPV, 
Barrett et al. (1993) designed a set of primers to 
diagnose RPV. Both RT-PCR techniques based on Np or 
Fp genes can be used for RPV diagnosis.  
The PCR has contributed to investigation of rinderpest 
during the present eradication programme. The potential-
ly very high DSn and DSp of the PCR make it ideal tool 
where the prevalence of RP is absent or very low, as is 
the case now in Africa. It must be stressed that if the RT-
PCR is linked to statistical viable sampling frames and 
that when collection of samples is made into protective 
solutions to maintain nucleic acid activity, then the PCR 
offers an ideal test for establishing disease status. Many 
laboratories in Africa can implement the PCR technique 
when constraints such as rapid clearance of fragile 
reagents such as enzymes at airports are solved and 
when properly designed PCR laboratories and techni-
cians are trained. There are good examples of the 
process of PCR equipment supply and training which 
began in about 1995 and are still being sustained by 
international organisations and the potential to perform 
PCR in control programmes is now present in many 
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